^
No biomarker
|
RCC
|
No biomarker
|
RCC
|
pembrolizumab + lenvatinib Sensitive: A1 - Approval
Merck (MSD) Press Release - 2 days
|
pembrolizumab + lenvatinib Sensitive: A1 - Approval
Merck (MSD) Press Release - 2 days
|
PBRM1 mutation
|
Clear Cell Renal Cell Carcinoma
|
PBRM1 mutation
|
Clear Cell Renal Cell Carcinoma
|
nivolumab Sensitive: C3 – Early Trials
Eur Urol - 1 week
|
nivolumab Sensitive: C3 – Early Trials
Eur Urol - 1 week
|
No biomarker
|
RCC
|
No biomarker
|
RCC
|
sunitinib Sensitive: A1 - Approval
ESMO.org - 2 weeks
|
sunitinib Sensitive: A1 - Approval
ESMO.org - 2 weeks
|
No biomarker
|
RCC
|
No biomarker
|
RCC
|
cabozantinib tablet Sensitive: A1 - Approval
ESMO.org - 2 weeks
|
cabozantinib tablet Sensitive: A1 - Approval
ESMO.org - 2 weeks
|
No biomarker
|
Clear Cell Renal Cell Carcinoma
|
No biomarker
|
Clear Cell Renal Cell Carcinoma
|
pembrolizumab + axitinib Sensitive: A2 - Guideline
ESMO.org - 2 weeks
|
pembrolizumab + axitinib Sensitive: A2 - Guideline
ESMO.org - 2 weeks
|
No biomarker
|
Clear Cell Renal Cell Carcinoma
|
No biomarker
|
Clear Cell Renal Cell Carcinoma
|
sunitinib Sensitive: A2 - Guideline
ESMO.org - 2 weeks
|
sunitinib Sensitive: A2 - Guideline
ESMO.org - 2 weeks
|
No biomarker
|
Clear Cell Renal Cell Carcinoma
|
No biomarker
|
Clear Cell Renal Cell Carcinoma
|
pazopanib Sensitive: A2 - Guideline
ESMO.org - 2 weeks
|
pazopanib Sensitive: A2 - Guideline
ESMO.org - 2 weeks
|
No biomarker
|
Clear Cell Renal Cell Carcinoma
|
No biomarker
|
Clear Cell Renal Cell Carcinoma
|
cabozantinib capsule Sensitive: A2 - Guideline
ESMO.org - 2 weeks
|
cabozantinib capsule Sensitive: A2 - Guideline
ESMO.org - 2 weeks
|
No biomarker
|
Clear Cell Renal Cell Carcinoma
|
No biomarker
|
Clear Cell Renal Cell Carcinoma
|
nivolumab + ipilimumab Sensitive: A2 - Guideline
ESMO.org - 2 weeks
|
nivolumab + ipilimumab Sensitive: A2 - Guideline
ESMO.org - 2 weeks
|
No biomarker
|
Clear Cell Renal Cell Carcinoma
|
No biomarker
|
Clear Cell Renal Cell Carcinoma
|
nivolumab + cabozantinib tablet Sensitive: A2 - Guideline
ESMO.org - 2 weeks
|
nivolumab + cabozantinib tablet Sensitive: A2 - Guideline
ESMO.org - 2 weeks
|
No biomarker
|
RCC
|
No biomarker
|
RCC
|
pembrolizumab Sensitive: A2 - Guideline
ESMO.org - 2 weeks
|
pembrolizumab Sensitive: A2 - Guideline
ESMO.org - 2 weeks
|
No biomarker
|
Clear Cell Renal Cell Carcinoma
|
No biomarker
|
Clear Cell Renal Cell Carcinoma
|
pembrolizumab + lenvatinib Sensitive: A2 - Guideline
ESMO.org - 2 weeks
|
pembrolizumab + lenvatinib Sensitive: A2 - Guideline
ESMO.org - 2 weeks
|
No biomarker
|
Clear Cell Renal Cell Carcinoma
|
No biomarker
|
Clear Cell Renal Cell Carcinoma
|
tivozanib Sensitive: A2 - Guideline
ESMO.org - 2 weeks
|
tivozanib Sensitive: A2 - Guideline
ESMO.org - 2 weeks
|
No biomarker
|
Clear Cell Renal Cell Carcinoma
|
No biomarker
|
Clear Cell Renal Cell Carcinoma
|
pembrolizumab Sensitive: A2 - Guideline
ESMO.org - 2 weeks
|
pembrolizumab Sensitive: A2 - Guideline
ESMO.org - 2 weeks
|
MET amplification
|
RCC
|
MET amplification
|
RCC
|
savolitinib Sensitive: A2 - Guideline
ESMO.org - 2 weeks
|
savolitinib Sensitive: A2 - Guideline
ESMO.org - 2 weeks
|
No biomarker
|
RCC
|
No biomarker
|
RCC
|
nivolumab + cabozantinib tablet Sensitive: A1 - Approval
|
nivolumab + cabozantinib tablet Sensitive: A1 - Approval
|
PD-L1 expression
|
RCC
|
PD-L1 expression
|
RCC
|
avelumab + axitinib Sensitive: A1 - Approval
|
avelumab + axitinib Sensitive: A1 - Approval
|
No biomarker
|
RCC
|
No biomarker
|
RCC
|
avelumab + axitinib Sensitive: A1 - Approval
|
avelumab + axitinib Sensitive: A1 - Approval
|
No biomarker
|
RCC
|
No biomarker
|
RCC
|
Mvasi (bevacizumab biosimilar) Sensitive: A1 - Approval
|
Mvasi (bevacizumab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
RCC
|
No biomarker
|
RCC
|
Zirabev (bevacizumab biosimilar) Sensitive: A1 - Approval
|
Zirabev (bevacizumab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
RCC
|
No biomarker
|
RCC
|
sorafenib Sensitive: A1 - Approval
|
sorafenib Sensitive: A1 - Approval
|
No biomarker
|
RCC
|
No biomarker
|
RCC
|
tivozanib Sensitive: A1 - Approval
|
tivozanib Sensitive: A1 - Approval
|
No biomarker
|
RCC
|
No biomarker
|
RCC
|
temsirolimus Sensitive: A1 - Approval
|
temsirolimus Sensitive: A1 - Approval
|
No biomarker
|
RCC
|
No biomarker
|
RCC
|
everolimus + lenvatinib Sensitive: A1 - Approval
|
everolimus + lenvatinib Sensitive: A1 - Approval
|
No biomarker
|
RCC
|
No biomarker
|
RCC
|
everolimus Sensitive: A1 - Approval
|
everolimus Sensitive: A1 - Approval
|
No biomarker
|
RCC
|
No biomarker
|
RCC
|
bevacizumab + pegylated interferon α -2a Sensitive: A1 - Approval
|
bevacizumab + pegylated interferon α -2a Sensitive: A1 - Approval
|
No biomarker
|
RCC
|
No biomarker
|
RCC
|
pembrolizumab + axitinib Sensitive: A1 - Approval
|
pembrolizumab + axitinib Sensitive: A1 - Approval
|
No biomarker
|
RCC
|
No biomarker
|
RCC
|
nivolumab Sensitive: A1 - Approval
|
nivolumab Sensitive: A1 - Approval
|
No biomarker
|
RCC
|
No biomarker
|
RCC
|
Aybintio (bevacizumab biosimilar) + pegylated interferon α -2a Sensitive: A1 - Approval
|
Aybintio (bevacizumab biosimilar) + pegylated interferon α -2a Sensitive: A1 - Approval
|
No biomarker
|
RCC
|
No biomarker
|
RCC
|
Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval
|
Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
RCC
|
No biomarker
|
RCC
|
nivolumab + ipilimumab Sensitive: A1 - Approval
|
nivolumab + ipilimumab Sensitive: A1 - Approval
|
No biomarker
|
RCC
|
No biomarker
|
RCC
|
axitinib Sensitive: A1 - Approval
|
axitinib Sensitive: A1 - Approval
|
No biomarker
|
RCC
|
No biomarker
|
RCC
|
pazopanib Sensitive: A1 - Approval
|
pazopanib Sensitive: A1 - Approval
|
No biomarker
|
RCC
|
No biomarker
|
RCC
|
aldesleukin Sensitive: A1 - Approval
|
aldesleukin Sensitive: A1 - Approval
|
No biomarker
|
RCC
|
No biomarker
|
RCC
|
Bevax (bevacizumab biosimilar) Sensitive: A1 - Approval
|
Bevax (bevacizumab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
RCC
|
No biomarker
|
RCC
|
Krabeva (bevacizumab biosimilar) Sensitive: A1 - Approval
|
Krabeva (bevacizumab biosimilar) Sensitive: A1 - Approval
|
VHL mutation
|
RCC
|
VHL mutation
|
RCC
|
belzutifan Sensitive: A1 - Approval
|
belzutifan Sensitive: A1 - Approval
|
No biomarker
|
RCC
|
No biomarker
|
RCC
|
bevacizumab Sensitive: A2 - Guideline
|
bevacizumab Sensitive: A2 - Guideline
|
No biomarker
|
Clear Cell Renal Cell Carcinoma
|
No biomarker
|
Clear Cell Renal Cell Carcinoma
|
bevacizumab + pegylated interferon α -2a Sensitive: A2 - Guideline
|
bevacizumab + pegylated interferon α -2a Sensitive: A2 - Guideline
|
No biomarker
|
Clear Cell Renal Cell Carcinoma
|
No biomarker
|
Clear Cell Renal Cell Carcinoma
|
avelumab + axitinib Sensitive: A2 - Guideline
|
avelumab + axitinib Sensitive: A2 - Guideline
|
No biomarker
|
RCC
|
No biomarker
|
RCC
|
bevacizumab + erlotinib Sensitive: A2 - Guideline
|
bevacizumab + erlotinib Sensitive: A2 - Guideline
|
No biomarker
|
RCC
|
No biomarker
|
RCC
|
erlotinib Sensitive: A2 - Guideline
|
erlotinib Sensitive: A2 - Guideline
|
No biomarker
|
Clear Cell Renal Cell Carcinoma
|
No biomarker
|
Clear Cell Renal Cell Carcinoma
|
temsirolimus Sensitive: A2 - Guideline
|
temsirolimus Sensitive: A2 - Guideline
|
No biomarker
|
Clear Cell Renal Cell Carcinoma
|
No biomarker
|
Clear Cell Renal Cell Carcinoma
|
sorafenib Sensitive: A2 - Guideline
|
sorafenib Sensitive: A2 - Guideline
|
No biomarker
|
Clear Cell Renal Cell Carcinoma
|
No biomarker
|
Clear Cell Renal Cell Carcinoma
|
lenvatinib Sensitive: A2 - Guideline
|
lenvatinib Sensitive: A2 - Guideline
|
No biomarker
|
Clear Cell Renal Cell Carcinoma
|
No biomarker
|
Clear Cell Renal Cell Carcinoma
|
axitinib Sensitive: A2 - Guideline
|
axitinib Sensitive: A2 - Guideline
|
No biomarker
|
Clear Cell Renal Cell Carcinoma
|
No biomarker
|
Clear Cell Renal Cell Carcinoma
|
everolimus Sensitive: A2 - Guideline
|
everolimus Sensitive: A2 - Guideline
|
No biomarker
|
Clear Cell Renal Cell Carcinoma
|
No biomarker
|
Clear Cell Renal Cell Carcinoma
|
bevacizumab Sensitive: A2 - Guideline
|
bevacizumab Sensitive: A2 - Guideline
|
PD-L1 expression
|
Clear Cell Renal Cell Carcinoma
|
PD-L1 expression
|
Clear Cell Renal Cell Carcinoma
|
pembrolizumab + axitinib Sensitive: B - Late Trials
|
pembrolizumab + axitinib Sensitive: B - Late Trials
|
PD-L1 expression
|
RCC
|
PD-L1 expression
|
RCC
|
nivolumab + cabozantinib tablet Sensitive: B - Late Trials
|
nivolumab + cabozantinib tablet Sensitive: B - Late Trials
|
MET mutation
|
RCC
|
MET mutation
|
RCC
|
savolitinib Sensitive: B - Late Trials
|
savolitinib Sensitive: B - Late Trials
|
No biomarker
|
RCC
|
No biomarker
|
RCC
|
belzutifan Sensitive: B - Late Trials
|
belzutifan Sensitive: B - Late Trials
|
PD-L1 expression
|
RCC
|
PD-L1 expression
|
RCC
|
pembrolizumab + axitinib Sensitive: B - Late Trials
|
pembrolizumab + axitinib Sensitive: B - Late Trials
|
PD-L1 expression
|
RCC
|
PD-L1 expression
|
RCC
|
bevacizumab + atezolizumab Sensitive: B - Late Trials
|
bevacizumab + atezolizumab Sensitive: B - Late Trials
|
ARID1A mutation
|
RCC
|
ARID1A mutation
|
RCC
|
sunitinib Sensitive: B - Late Trials
|
sunitinib Sensitive: B - Late Trials
|
MTOR mutation
|
RCC
|
MTOR mutation
|
RCC
|
sunitinib Sensitive: B - Late Trials
|
sunitinib Sensitive: B - Late Trials
|
ROBO3 mutation
|
RCC
|
ROBO3 mutation
|
RCC
|
sunitinib Sensitive: B - Late Trials
|
sunitinib Sensitive: B - Late Trials
|
FLT1 rs9554320
|
RCC
|
FLT1 rs9554320
|
RCC
|
sunitinib Sensitive: B - Late Trials
|
sunitinib Sensitive: B - Late Trials
|
KDR rs2071559
|
RCC
|
KDR rs2071559
|
RCC
|
sunitinib Sensitive: B - Late Trials
|
sunitinib Sensitive: B - Late Trials
|
PD-L1 expression
|
RCC
|
PD-L1 expression
|
RCC
|
nivolumab + ipilimumab Sensitive: B - Late Trials
|
nivolumab + ipilimumab Sensitive: B - Late Trials
|
AXL-L
|
RCC
|
AXL-L
|
RCC
|
cabozantinib tablet Sensitive: B - Late Trials
|
cabozantinib tablet Sensitive: B - Late Trials
|
MSI-H/dMMR
|
RCC
|
MSI-H/dMMR
|
RCC
|
dostarlimab Sensitive: C1 - Off-label
|
dostarlimab Sensitive: C1 - Off-label
|
VHL mutation
|
Clear Cell Renal Cell Carcinoma
|
VHL mutation
|
Clear Cell Renal Cell Carcinoma
|
belzutifan Sensitive: C1 - Off-label
|
belzutifan Sensitive: C1 - Off-label
|
PD-L1 expression
|
RCC
|
PD-L1 expression
|
RCC
|
atezolizumab Sensitive: C1 - Off-label
|
atezolizumab Sensitive: C1 - Off-label
|
BRCA1 mutation
|
RCC
|
BRCA1 mutation
|
RCC
|
olaparib Sensitive: C1 - Off-label
|
olaparib Sensitive: C1 - Off-label
|
BRCA2 mutation
|
RCC
|
BRCA2 mutation
|
RCC
|
olaparib Sensitive: C1 - Off-label
|
olaparib Sensitive: C1 - Off-label
|
PD-L1 expression
|
RCC
|
PD-L1 expression
|
RCC
|
pembrolizumab Sensitive: C1 - Off-label
|
pembrolizumab Sensitive: C1 - Off-label
|
VHL mutation
|
Clear Cell Renal Cell Carcinoma
|
VHL mutation
|
Clear Cell Renal Cell Carcinoma
|
PT2385 Sensitive: C2 – Inclusion Criteria
|
PT2385 Sensitive: C2 – Inclusion Criteria
|
MTOR mutation
|
RCC
|
MTOR mutation
|
RCC
|
everolimus Sensitive: C2 – Inclusion Criteria
|
everolimus Sensitive: C2 – Inclusion Criteria
|
PD-L1 expression
|
RCC
|
PD-L1 expression
|
RCC
|
avelumab Sensitive: C2 – Inclusion Criteria
|
avelumab Sensitive: C2 – Inclusion Criteria
|
MET amplification
|
RCC
|
MET amplification
|
RCC
|
crizotinib Sensitive: C2 – Inclusion Criteria
|
crizotinib Sensitive: C2 – Inclusion Criteria
|
KIM1 expression
|
RCC
|
KIM1 expression
|
RCC
|
CDX-014 Sensitive: C2 – Inclusion Criteria
|
CDX-014 Sensitive: C2 – Inclusion Criteria
|
PD-L1 expression
|
RCC
|
PD-L1 expression
|
RCC
|
nivolumab Sensitive: C2 – Inclusion Criteria
|
nivolumab Sensitive: C2 – Inclusion Criteria
|
FLCN mutation
|
RCC
|
FLCN mutation
|
RCC
|
everolimus Sensitive: C2 – Inclusion Criteria
|
everolimus Sensitive: C2 – Inclusion Criteria
|
PD-L1 expression
|
RCC
|
PD-L1 expression
|
RCC
|
bevacizumab + albumin-bound paclitaxel + IPI-549 Sensitive: C2 – Inclusion Criteria
|
bevacizumab + albumin-bound paclitaxel + IPI-549 Sensitive: C2 – Inclusion Criteria
|
PD-L1 expression
|
RCC
|
PD-L1 expression
|
RCC
|
bevacizumab + atezolizumab + IPI-549 Sensitive: C2 – Inclusion Criteria
|
bevacizumab + atezolizumab + IPI-549 Sensitive: C2 – Inclusion Criteria
|
MET mutation
|
RCC
|
MET mutation
|
RCC
|
cabozantinib capsule Sensitive: C2 – Inclusion Criteria
|
cabozantinib capsule Sensitive: C2 – Inclusion Criteria
|
TFE3 translocation
|
RCC
|
TFE3 translocation
|
RCC
|
cabozantinib tablet Sensitive: C2 – Inclusion Criteria
|
cabozantinib tablet Sensitive: C2 – Inclusion Criteria
|
MET mutation
|
RCC
|
MET mutation
|
RCC
|
crizotinib Sensitive: C2 – Inclusion Criteria
|
crizotinib Sensitive: C2 – Inclusion Criteria
|
HDAC2 expression
|
RCC
|
HDAC2 expression
|
RCC
|
pazopanib + CG-781 Sensitive: C3 – Early Trials
|
pazopanib + CG-781 Sensitive: C3 – Early Trials
|
PBRM1 underexpression
|
RCC
|
PBRM1 underexpression
|
RCC
|
sorafenib Resistant: C3 – Early Trials
|
sorafenib Resistant: C3 – Early Trials
|
PBRM1 overexpression
|
RCC
|
PBRM1 overexpression
|
RCC
|
sorafenib Sensitive: C3 – Early Trials
|
sorafenib Sensitive: C3 – Early Trials
|
PD-1-H
|
RCC
|
PD-1-H
|
RCC
|
sunitinib Resistant: C3 – Early Trials
|
sunitinib Resistant: C3 – Early Trials
|
SETD2 mutation
|
Clear Cell Renal Cell Carcinoma
|
SETD2 mutation
|
Clear Cell Renal Cell Carcinoma
|
Immunotherapy Resistant: C3 – Early Trials
|
Immunotherapy Resistant: C3 – Early Trials
|
ERVE-4 expression
|
Clear Cell Renal Cell Carcinoma
|
ERVE-4 expression
|
Clear Cell Renal Cell Carcinoma
|
nivolumab Sensitive: C3 – Early Trials
|
nivolumab Sensitive: C3 – Early Trials
|
HAVCR2 expression
|
RCC
|
HAVCR2 expression
|
RCC
|
nivolumab + ipilimumab Sensitive: C3 – Early Trials
|
nivolumab + ipilimumab Sensitive: C3 – Early Trials
|
HAVCR2 expression
|
RCC
|
HAVCR2 expression
|
RCC
|
nivolumab Sensitive: C3 – Early Trials
|
nivolumab Sensitive: C3 – Early Trials
|
VEGFA-H
|
RCC
|
VEGFA-H
|
RCC
|
pazopanib Resistant: C3 – Early Trials
|
pazopanib Resistant: C3 – Early Trials
|
CXCL12-H
|
RCC
|
CXCL12-H
|
RCC
|
pazopanib Resistant: C3 – Early Trials
|
pazopanib Resistant: C3 – Early Trials
|
SPP1-L
|
RCC
|
SPP1-L
|
RCC
|
pazopanib Sensitive: C3 – Early Trials
|
pazopanib Sensitive: C3 – Early Trials
|
HGF-L
|
RCC
|
HGF-L
|
RCC
|
pazopanib Sensitive: C3 – Early Trials
|
pazopanib Sensitive: C3 – Early Trials
|
CXCL8-L
|
RCC
|
CXCL8-L
|
RCC
|
pazopanib Sensitive: C3 – Early Trials
|
pazopanib Sensitive: C3 – Early Trials
|
IL6-L
|
RCC
|
IL6-L
|
RCC
|
pazopanib Sensitive: C3 – Early Trials
|
pazopanib Sensitive: C3 – Early Trials
|
PAI1-H
|
RCC
|
PAI1-H
|
RCC
|
axitinib Resistant: C3 – Early Trials
|
axitinib Resistant: C3 – Early Trials
|
HGF expression
|
RCC
|
HGF expression
|
RCC
|
lenvatinib Sensitive: C3 – Early Trials
|
lenvatinib Sensitive: C3 – Early Trials
|
IL18 expression
|
RCC
|
IL18 expression
|
RCC
|
lenvatinib Sensitive: C3 – Early Trials
|
lenvatinib Sensitive: C3 – Early Trials
|
ANGPT2 expression
|
RCC
|
ANGPT2 expression
|
RCC
|
lenvatinib Sensitive: C3 – Early Trials
|
lenvatinib Sensitive: C3 – Early Trials
|
TIMP1 expression
|
RCC
|
TIMP1 expression
|
RCC
|
lenvatinib Sensitive: C3 – Early Trials
|
lenvatinib Sensitive: C3 – Early Trials
|
CSF1 expression
|
RCC
|
CSF1 expression
|
RCC
|
lenvatinib Sensitive: C3 – Early Trials
|
lenvatinib Sensitive: C3 – Early Trials
|
VEGFA expression
|
RCC
|
VEGFA expression
|
RCC
|
lenvatinib Sensitive: C3 – Early Trials
|
lenvatinib Sensitive: C3 – Early Trials
|
CXCL9 expression
|
RCC
|
CXCL9 expression
|
RCC
|
lenvatinib Sensitive: C3 – Early Trials
|
lenvatinib Sensitive: C3 – Early Trials
|
IL18BP expression
|
RCC
|
IL18BP expression
|
RCC
|
lenvatinib Sensitive: C3 – Early Trials
|
lenvatinib Sensitive: C3 – Early Trials
|
SYNE1 mutation
|
Clear Cell Renal Cell Carcinoma
|
SYNE1 mutation
|
Clear Cell Renal Cell Carcinoma
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
PD-L1 expression
|
RCC
|
PD-L1 expression
|
RCC
|
pembrolizumab + lenvatinib Sensitive: C3 – Early Trials
|
pembrolizumab + lenvatinib Sensitive: C3 – Early Trials
|
Chr del(9)(p21.3)
|
RCC
|
Chr del(9)(p21.3)
|
RCC
|
PD-L1 inhibitor Resistant: C3 – Early Trials
|
PD-L1 inhibitor Resistant: C3 – Early Trials
|
CXCL8 elevation
|
RCC
|
CXCL8 elevation
|
RCC
|
atezolizumab Resistant: C3 – Early Trials
|
atezolizumab Resistant: C3 – Early Trials
|
IFNG gene signature overexpression
|
RCC
|
IFNG gene signature overexpression
|
RCC
|
nivolumab + BMS-986205 Sensitive: C3 – Early Trials
|
nivolumab + BMS-986205 Sensitive: C3 – Early Trials
|
